Cite
MLA Citation
P McLaughlin et al.. “Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program.” Journal of clinical oncology, vol. 41, no. 2, 2023, pp. 154–162. http://access.bl.uk/ark:/81055/vdc_100174254206.0x000001